• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effectiveness and safety of transcatheter left atrial appendage closure
J Cardiol. 2021 Sep 23:S0914-5087(21)00234-3. doi: 10.1016/j.jjcc.2021.08.031. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is responsible for cardiogenic stroke. Since left atrial appendage (LAA) is a cause of most of cardiac thrombus, LAA closure is an emerging novel stroke prevention procedure for patients with AF alternative to anticoagulation. WATCHMAN LAA Closure device (Boston Scientific, Marlborough, MA, USA) is the only approved device in the USA and Japan. The device is indicated in high bleeding risk and high stroke risk non-valvular AF patients. Cardiac tamponade, stroke, and device embolization are t...
Source: Journal of Cardiology - September 27, 2021 Category: Cardiology Authors: Yoshifumi Nakajima Source Type: research

Bleeding Outcomes After Percutaneous Coronary Intervention in the Past Two Decades in Japan 　- From the CREDO-Kyoto Registry Cohort-2 and Cohort-3
CONCLUSIONS: In this historical comparative study, Cohort-3 compared with Cohort-2 was associated with excess bleeding risk, which might be at least partly explained by the difference in P2Y12receptor blockers.PMID:34526432 | DOI:10.1253/circj.CJ-21-0526
Source: Circulation Journal - September 16, 2021 Category: Cardiology Authors: Masahiro Natsuaki Takeshi Morimoto Hiroki Shiomi Ko Yamamoto Kyohei Yamaji Hirotoshi Watanabe Takashi Uegaito Mitsuo Matsuda Toshihiro Tamura Ryoji Taniguchi Moriaki Inoko Hiroshi Mabuchi Teruki Takeda Takenori Domei Manabu Shirotani Natsuhiko Ehara Hiros Source Type: research

Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data
This study suggested that in the current use of DOACs in Japanese patients with NVAF, dabigatran had a significantly lower risk of major bleeding than apixaban, but there was no significant difference in effectiveness among the four DOACs.PMID:34471057 | DOI:10.1248/bpb.b21-00230
Source: Biological and Pharmaceutical Bulletin - September 2, 2021 Category: Drugs & Pharmacology Authors: Aya Enomoto Yasunari Mano Yohei Kawano Tomoki Nishikawa Takao Aoyama Yoshiyuki Sasaki Masashi Nagata Hiromitsu Takahashi Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16